Literature DB >> 9188635

Genotypic and phenotypic characterization of long terminal repeat sequences from long-term survivors of human immunodeficiency virus type 1 infection.

L Zhang1, Y Huang, H Yuan, B K Chen, J Ip, D D Ho.   

Abstract

Human immunodeficiency virus type 1 (HIV-1)-infected individuals who remain asymptomatic despite prolonged infection present a unique opportunity to understand virologic and immunologic factors involved in the pathogenesis of AIDS. We have previously identified a group of long-term survivors (LTS) who are clinically healthy and immunologically normal despite 13 to 15 years of HIV-1 infection. In this study, we examined the 5' long terminal repeat (5' LTR) sequences in eight of these LTS. A total of 29 nucleotide sequences were obtained from their peripheral blood mononuclear cells (PBMC). Analysis of these sequences revealed no gross deletions within the 5' LTR. Seven of the eight subjects shared nearly identical consensus sequences in the binding sites for NF-kappaB, Sp1, and the viral trans-activator Tat. In multiple samples from one individual (Pt 5), however, G-to-A hypermutations were found throughout the entire region, suggesting a genetically defective 5' LTR. The effects of the observed genetic variations on LTR transcription were studied by transient transfection of an LTR-driven luciferase reporter gene and by infection with a full-length recombinant HIV-1 containing a luciferase reporter (HIVHXBLTRluc). A wide range of basal and Tat-induced transcriptional activities was found among the 5' LTR from seven of the eight LTS in both transfected 293 cells and donor PBMC, suggesting a functionally intact 5' LTR in these individuals. It is therefore unlikely that defects in the 5' LTR are the underlying explanation for the benign clinical course associated with these seven individuals. However, functional abnormalities were found in the LTR from Pt 5 in directing both heterologous and viral gene expression, providing a possible genetic explanation for the low viral load and prolonged asymptomatic state of this individual. Last, a similar overall degree of genetic diversity was found among viruses from the LTS compared to those from patients with AIDS, reinforcing the notion that a strong correlation between the degree of genetic diversity and the rate of disease progression is unlikely.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9188635      PMCID: PMC191803          DOI: 10.1128/JVI.71.7.5608-5613.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

Review 1.  Sequence variability in human immunodeficiency viruses: pattern and process in viral evolution.

Authors:  A J Brown
Journal:  AIDS       Date:  1991       Impact factor: 4.177

2.  HIV pathogenesis and long-term survival.

Authors:  J A Levy
Journal:  AIDS       Date:  1993-11       Impact factor: 4.177

3.  Summary of the epidemiology of HIV/AIDS in Japan.

Authors:  T Kitamura
Journal:  AIDS       Date:  1994       Impact factor: 4.177

4.  Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.

Authors:  F Kirchhoff; T C Greenough; D B Brettler; J L Sullivan; R C Desrosiers
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

5.  Studies in subjects with long-term nonprogressive human immunodeficiency virus infection.

Authors:  G Pantaleo; S Menzo; M Vaccarezza; C Graziosi; O J Cohen; J F Demarest; D Montefiori; J M Orenstein; C Fox; L K Schrager
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

6.  Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.

Authors:  Y Cao; L Qin; L Zhang; J Safrit; D D Ho
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

7.  Differential growth kinetics are exhibited by human immunodeficiency virus type 1 TAR mutants.

Authors:  D Harrich; C Hsu; E Race; R B Gaynor
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

8.  Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection.

Authors:  Y Huang; L Zhang; D D Ho
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

9.  Naturally occurring genotypes of the human immunodeficiency virus type 1 long terminal repeat display a wide range of basal and Tat-induced transcriptional activities.

Authors:  N L Michael; L D'Arcy; P K Ehrenberg; R R Redfield
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

10.  A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation.

Authors:  N D Perkins; N L Edwards; C S Duckett; A B Agranoff; R M Schmid; G J Nabel
Journal:  EMBO J       Date:  1993-09       Impact factor: 11.598

View more
  14 in total

1.  Genetic analysis of the long terminal repeat (LTR) promoter region in HIV-1-infected individuals with different rates of disease progression.

Authors:  Eva Ramírez de Arellano; Cristina Martín; Vincent Soriano; José Alcamí; Africa Holguín
Journal:  Virus Genes       Date:  2006-12-09       Impact factor: 2.332

Review 2.  Genetic variation and HIV-associated neurologic disease.

Authors:  Satinder Dahiya; Bryan P Irish; Michael R Nonnemacher; Brian Wigdahl
Journal:  Adv Virus Res       Date:  2013       Impact factor: 9.937

Review 3.  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Authors:  K Ikuta; S Suzuki; H Horikoshi; T Mukai; R B Luftig
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

4.  Genotypic and phenotypic heterogeneity in the U3R region of HIV type 1 subtype C.

Authors:  Jessica M Mates; Surender B Kumar; Jose Bazan; Megan Mefford; Igor Voronkin; Samuel Handelman; Victor Mwapasa; William Ackerman; Daniel Janies; Jesse J Kwiek
Journal:  AIDS Res Hum Retroviruses       Date:  2013-08-12       Impact factor: 2.205

Review 5.  BK polyomavirus diversity-Why viral variation matters.

Authors:  Jason T Blackard; Stella M Davies; Benjamin L Laskin
Journal:  Rev Med Virol       Date:  2020-03-03       Impact factor: 6.989

6.  Structural and functional evolution of human immunodeficiency virus type 1 long terminal repeat CCAAT/enhancer binding protein sites and their use as molecular markers for central nervous system disease progression.

Authors:  Tricia H Hogan; Devin L Stauff; Fred C Krebs; Suzanne Gartner; Shane J Quiterio; Brian Wigdahl
Journal:  J Neurovirol       Date:  2003-02       Impact factor: 2.643

7.  Persistent antibody responses but declining cytotoxic T-lymphocyte responses to multiple human immunodeficiency virus type 1 antigens in a long-term nonprogressing individual with a defective p17 proviral sequence and no detectable viral RNA expression.

Authors:  J M Binley; X Jin; Y Huang; L Zhang; Y Cao; D D Ho; J P Moore
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

8.  Naturally occurring human immunodeficiency virus type 1 long terminal repeats have a frequently observed duplication that binds RBF-2 and represses transcription.

Authors:  M C Estable; B Bell; M Hirst; I Sadowski
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

9.  Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy.

Authors:  Hiroyu Hatano; Eric L Delwart; Philip J Norris; Tzong-Hae Lee; Joan Dunn-Williams; Peter W Hunt; Rebecca Hoh; Susan L Stramer; Jeffrey M Linnen; Joseph M McCune; Jeffrey N Martin; Michael P Busch; Steven G Deeks
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

10.  Analysis of infectious virus clones from two HIV-1 superinfection cases suggests that the primary strains have lower fitness.

Authors:  Antoinette C van der Kuyl; Karolina Kozaczynska; Kevin K Ariën; Youssef Gali; Victoria R Balázs; Stefan J Dekker; Fokla Zorgdrager; Guido Vanham; Ben Berkhout; Marion Cornelissen
Journal:  Retrovirology       Date:  2010-07-20       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.